-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The research team from Helmholtz Munich, the German Diabetes Research Center (DZD) and Novo Nordisk has developed a new combination of hormones for the future treatment of type 2 diabetes
The drug tesaglitazar improves glucose and fat metabolism
This new drug improves glucose tolerance and glucose metabolism
The new drug has been successfully tested in animal studies: "Obese and diabetic male mice had much greater improvements in glucose metabolism compared to treatment with the GLP-1 hormone or Tesaglitazar alone, and there were no damaging adverse effects on the liver or kidneys," said
The researchers now want to investigate whether the drug also has the potential to treat type 2 diabetes in humans, and whether the efficacy of this new combination therapy can be further optimized
GLP-1-mediated delivery of Tesaglitazar improves obesity and glucose metabolism in male mice